Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry
In recent years, the biopharmaceutical industry has seen an increase in the development of so-called orphan drugs for the treatment of rare and neglected diseases. This increase has been spurred on by legislation in the United States, Europe, and elsewhere designed to promote orphan drug development...
| Authors: | ; ; ; ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Springer Science + Business Media B. V
2013
|
| In: |
Journal of business ethics
Year: 2013, Volume: 117, Issue: 1, Pages: 45-65 |
| Further subjects: | B
rare diseases
B European Union (EU) B orphan drugs B United States (US) B Corporate social responsibility (CSR) B Strategic CSR B Biopharmaceutical industry |
| Online Access: |
Volltext (JSTOR) Volltext (lizenzpflichtig) |